Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
- Resource Type
- Authors
- Patrice Rodien; Alexandre Collin; Philippe Menei; Marie-Christine Rousselet; Claire Briet; Valentine Suteau
- Source
- Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, Springer Verlag, 2020, 69 (10), pp.2053-2061. ⟨10.1007/s00262-020-02611-x⟩
- Subject
- Male
Cancer Research
Pathology
medicine.medical_specialty
[SDV]Life Sciences [q-bio]
medicine.medical_treatment
Immunology
Clone (cell biology)
Neuroendocrine tumors
B7-H1 Antigen
03 medical and health sciences
0302 clinical medicine
PD-L1
Biomarkers, Tumor
Humans
Immunology and Allergy
Medicine
Pituitary Neoplasms
ComputingMilieux_MISCELLANEOUS
Retrospective Studies
biology
business.industry
Pituitary tumors
Immunotherapy
Middle Aged
Prognosis
medicine.disease
3. Good health
Survival Rate
Neuroendocrine Tumors
Oncology
biology.protein
Immunohistochemistry
Female
Neoplasm Recurrence, Local
Antibody
business
Immunostaining
Follow-Up Studies
030215 immunology
- Language
- ISSN
- 1432-0851
0340-7004
To explore the programmed death-ligand 1 (PD-L1) expression in varied subtypes of pituitary neuroendocrine tumors with assessment of their clinical behavior at diagnosis and follow-up. We conducted a retrospective monocentric study, including all patients operated in the Academic Hospital of Angers (France) for a pituitary neuroendocrine tumor between 2012 and 2018. PDL-1 immunostaining was performed using a European Conformity—In Vitro Diagnostic-labeled anti-PDL1 antibody (clone 22C3). PD-L1 immunostaining was evaluated as the percentage of tumor cells showing positive membrane staining, into four grades: grade 0 =